Naslov
Expression of XOX-A9 in acute leukemia

Autori
Golemović, Mirna ; Ćurić, Josip ; Dubravčić, Klara ; Užarević, Branka ; Boban, Dubravka ; Sučić, Mirna ; Ries, Sunčica ; Gjadrov, Koraljka ; Zadro, Renata ; Bogdanić, Vinko ; Nemet, Damir ; Mrsić, Mirando ; Rajić, Ljubica ; Femenić, Ranka ; Konja, Josip ; Labar, Boris ; Batinić, Drago

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts of the 7th Annual Meeting of the European Hematology Association ; u: The Hematology Journal 3 (2002) (S1) / Goldman, John ; Foa, Robin - Basingstoke : New York (NY) : Nature publishing group, 2002, 389-389

Skup
Annual Meeting of the European Hematology Association (7 ; 2002)

Mjesto i datum
Firenca, Italija, 06.06.2002. - 09.06.2002

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
HOXA9; acute leukemia

Sažetak
In this study the expression pattern of HOXA9 in cell samples collected from patients with hematological malignancies was investigated. By using RT-PCR we analyzed the expression of HOXA9 in 36 AL samples (14 AML, 12 ALL and 10 mixed or biphenotypic AL - BAL), 4 B-CLL, several leukemia cell lines (K562, HL60, SU-DHL4 and NALM-6) as well as in control samples from healthy donors (peripheral blood and bone marrow mononuclear cells, PBMNC and BMMNC, respectively). In contrast to PBMNC, HOXA9 was found in bone marrow MNC of a healthy donor. In acute leukemia, HOXA9 was expressed in 79% (11/14) of AML, 60% (6/10) of BAL and, the most interesting finding, in 15% (2/12) of ALL samples. In relation to FAB and/or immunophenotype, HOXA9 was present in 1/2 FAB-M1, 2/4 FAB-M2, 2/2 FAB-M3, 3/3 FAB-M4, 2/2 FAB-M5a and in one FAB-unclassified MPO+CD13+ AL. Among ALL patients, HOXA9 was expressed in 0/4 T-ALL, 1/1 pro-B, 0/6 "common" -ALL, and 1/1 B-ALL whereas in biphenotypic AL the HOXA9 message was present in 1/1 FAB-M1, 0/2 FAB-M5a, 2/4 FAB-L2, 2/2 FAB-UAL and in 1/1 biclonal BAL. Among the cell lines tested, HOXA9 was found in cells with myeloid differentiation (HL60 and K562), but also in pre-B cell line NALM6. Although preferentially expressed in leukemic cells with myeloid commitment, the expression of HOXA9 in B-lineage ALL is consistent with its finding in pre-B cell line NALM6. Further studies are needed to correlate leukemia HOXA9 gene expression with biological and clinical behaviour of AL.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA